Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment
Bibliographic record
Abstract
Abstract Background: Given the introduction of 2nd generation safer and more tolerable BTKis to treat first- line Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) patients, Integra Connect evaluated the use of these therapies among patients at practices who participated in its quality improvement (QI) program focusing on the use of 2nd generation BTKi drugs in the treatment of CLL/SLL compared to those practices who did not participate to assess the use of the 1st generation BTKi (ibrutinib) and the impact of CV-ME on treatment. Methods: The Integra Connect PrecisionQ real-world de-identified database was used to identify patients who initiated first- line treatment for CLL/SLL between January 1, 2023 and December 31, 2024. The analysis included practices who participated in the QI in 2023 (Group A) and those practices who did not participate (Group B). Descriptive statistics were used to assess proportions and chi-squared analysis were used to test for significance. Results: Among Group A practices, 802 patients received first-line treatment with 55.7% receiving a BTKi. Among Group B practices, 2,508 patients received first-line treatment with 59.3% receiving a BTKi. In Group A practices, the use of ibrutinib was 4.9% overall and 8.7% among patients treated with a BTKi, whereas among Group B practices the use of ibrutinib was 10% overall and 16.8% among the patients treated with a BTKi (p<0.01). Patients treated with ibrutinib in first-line experienced a CV-ME 9.7% of the time whereas those on a 2nd generation BTKi experienced a CV-ME 7.1% of the time (p>0.05). Conclusion: Those practices that participated in the CLL/SLL QI had increased guideline concordance per the NCCN of using 2nd generation BTKi drugs and had lower rates of CV-ME due to the lower use of ibrutinib in the treatment of CLL/SLL patients in the first-line.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.006 | 0.016 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.002 | 0.003 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".